Abstract: The instant disclosure provides norovirus binding aptamers, compositions comprising such aptamers, and methods of using and producing such aptamers. The aptamers are useful, for example, for detecting the presence of norovirus in test samples, for capturing and/or concentrating norovirus from test samples, for evaluating the efficacy of therapeutic agents in patients diagnosed with a norovirus infection, and for evaluating the efficacy of norovirus vaccines.
Type:
Grant
Filed:
June 12, 2015
Date of Patent:
June 4, 2019
Assignee:
NORTH CAROLINA STATE UNIVERSITY
Inventors:
Lee-Ann Jaykus, Blanca Irene Escudero-Abarca, Matthew D. Moore, Helen Rawsthorne
Abstract: The present invention includes compositions and methods of inhibiting or activating TLR7 signaling. In one aspect, a composition includes an inhibitor of TLR7 signaling is described, where the inhibitor of TLR7 signaling is a TLR7 inhibitory oligonucleotide, a TLR7 antibody, or a TLR7 antagonist. In another aspect, a composition and method are described for preventing and treating viral infection of a T cell in a subject. Methods for decreasing T cell proliferation by administering a composition with a TLR7 ligand or agonist or inducing T cell anergy in a subject by stimulating T cells with a TLR7 ligand or agonist are also described.
Type:
Grant
Filed:
June 18, 2015
Date of Patent:
June 4, 2019
Assignee:
Yale University
Inventors:
Margarita Dominguez-Villar, David A. Hafler
Abstract: The present invention relates to compositions and methods of treating warts and other human papilloma virus (HPV) skin infections. The present invention relates to compositions and methods of treating skin cancer.
Type:
Grant
Filed:
November 4, 2014
Date of Patent:
May 28, 2019
Assignee:
Phio Pharmaceuticals Corp.
Inventors:
William R. Levis, Leonard L. Kaplan, John G. Callahan
Abstract: Novel compositions useful as influenza immunogens are provided. The compositions enable a host response to immunogen sites normally not recognized by a host.
Type:
Grant
Filed:
July 16, 2015
Date of Patent:
May 28, 2019
Assignee:
Biological Mimetics, Inc.
Inventors:
Peter L Nara, Gregory J Tobin, George Lin
Abstract: The invention relates to non-integrative lentiviral vectors and their use for the stable transgenesis of both dividing and no-dividing eukaryotic cells. The invention also provides methods for obtaining these vectors, the use of these vectors for the production of recombinant lentiviruses, and the use of these recombinant lentiviruses for obtaining a cell able to stably produce a product of interest.
Type:
Grant
Filed:
November 27, 2014
Date of Patent:
May 21, 2019
Assignee:
FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES CARIOVASCULARES CARLOS III (CNIC)
Inventors:
Juan Carlos Ramírez Martínez, Raúl Torres Ruiz, Aida García Torralba
Abstract: The object of the present invention is to provide a new therapeutic method and a new therapeutic agent that are different from known therapeutic medicines for human T cell leukemia virus type-1 (also known as human T lymphotropic virus type-1) associated myelopathy (HAM) patients and asymptomatic HTLV-1 carriers. The present invention relates to a therapeutic method and a therapeutic agent for human T cell leukemia virus type-1 (HTLV-1) associated myelopathy (HAM) patients and asymptomatic HTLV-1 carriers (ACs), which is characterized by reducing HTLV-1 virus-infected cells using an anti-human CC-chemokine receptor 4 (CCR4) antibody.
Type:
Grant
Filed:
March 31, 2017
Date of Patent:
May 21, 2019
Assignees:
ST. MARIANNA UNIVERSITY SCHOOL OF MEDICINE, KYOWA HAKKO KIRIN CO., LTD
Abstract: The present invention provides AAV capsid proteins comprising modification of one or a combination of the surface-exposed lysine, serine, threonine and/or tyrosine residues in the VP3 region. Also provided are rAAV virions comprising the AAV capsid proteins of the present invention, as well as nucleic acid molecules and rAAV vectors encoding the AAV capsid proteins of the present invention. Advantageously, the rAAV vectors and virions of the present invention have improved efficiency in transduction of a variety of cells, tissues and organs of interest, when compared to wild-type rAAV vectors and virions.
Type:
Grant
Filed:
February 27, 2017
Date of Patent:
May 21, 2019
Assignee:
University of Florida Research Foundation, Incorporated
Inventors:
Arun Srivastava, George Vladimirovich Aslanidi, Kim M. Van Vliet, Mavis Agbandje-McKenna
Abstract: Methods of treating a patient with human immunodeficiency virus are disclosed. The method includes a providing intradermal and intravenous doses of a aTh1 composition that can increase the CD4+ cells in a patient that are resistant to HIV. The description includes a method for viral load reduction and a viral purge method. The regimen leads to a spike in the viral load and a then a return to baseline or lower levels of the virus and can lead to reduction and/or elimination of the latent viral reservoirs. Kits configured to provide intradermal doses and intravenous doses according to the regimen are also included.
Abstract: Immunogenic compositions containing a human immunodeficiency virus (HIV) gp140 protein, sorbitol, polysorbate 20, and histidine buffer are described. The described immunogenic compositions are advantageous in that they are stable at refrigerated temperature for extended periods of time, and are compatible with an adjuvant. Also described are methods of using the immunogenic compositions to induce an immune response against an HIV in a subject. The immunogenic compositions can be administered alone, or in combination with one or more additional HIV antigens, or one or more adenovirus vectors encoding the one or more additional HIV antigens.
Abstract: A new non-HIV vaccine antigen from Mycoplasma sp. permease capable of inducing a mucosal neutralizing protective antibody response against HIV infection, a neutralizing antibody directed to said antigen, and a method for the identification of new antigens from the mucosal microbiota for the development of vaccines against pathogens.
Type:
Grant
Filed:
February 5, 2015
Date of Patent:
April 30, 2019
Assignee:
B Cell Design SAS
Inventors:
Raphaëlle Claude El Habib, Régis Sodoyer, Armelle Cuvillier, Christiane Moog
Abstract: Disclosed herein are single nucleic acid constructs comprising a vector, wherein the vector comprises: a first nucleic acid sequence, wherein the first nucleic acid sequence comprises one or more antigenic sequences of interest, one or more spacer sequences and one or more hydrophobic anchor sequences, operably linked to a first transcriptional control element; a second nucleic acid sequence, wherein the second nucleic acid sequence comprises one or more pathogen-associated molecular pattern (PAMP) sequences operably linked to a second transcriptional control element; a third nucleic acid sequence, wherein the third nucleic acid sequence comprises one or more cell surface receptor binding sequences operably linked to a third transcriptional control element; and a selectable marker. Also described herein, are methods of making the single nucleic acid constructs and methods of administering the single nucleic acid constructs for the treatment or prevention of infections and cancer.
Abstract: Methods and systems for purifying one or more microbial cells and/or viruses from a biological sample are provided. The biological sample is added to a well disposed in a medium. A potential is applied across the medium to cause the contaminants to enter one or more walls of the well, and retain the microbial cells and/or viruses in the well. The microbial cells and/or viruses can be removed from the well, and optionally adhered or fixed to a surface, or detected. In one embodiment, the microbial cells and/or viruses are retained in the well by embedding in the medium. The medium including the embedded microbial cells and/or viruses may be excised or otherwise removed and transferred to a glass slide or other solid surface.
Type:
Grant
Filed:
May 3, 2017
Date of Patent:
April 9, 2019
Assignee:
Accelerate Diagnostics, Inc.
Inventors:
Landon Prisbrey, Elise Blackmore, Kenneth R. Hance, Steven W. Metzger, Kevin Marshall
Abstract: Provided are antigenic polypeptides of HIV envelope glycoproteins which are constructed based on amino acid mutation of attenuated live vaccine of Equine Infectious Anemia Virus, DNA constructions and recombinant virus vectors comprising polynucleotides encoding said polypeptides, antibodies against said polypeptides as well as uses thereof in preventing and treating HIV infection. Said antigenic polypeptides and vaccines can induce high titer neutralization antibodies against HIV in organism.
Type:
Grant
Filed:
January 21, 2015
Date of Patent:
April 9, 2019
Assignee:
National Center for AIDS/STD Control And Prevention, Chinese Center for Disease Control and Prevention
Abstract: The invention provides methods for the identification of patients capable of controlling HIV progression, as well as to the identification of an antagonist form of IP-10 associated to HIV progression control and the uses thereof for improving the immunological response of HIV patients.
Type:
Grant
Filed:
October 31, 2016
Date of Patent:
April 9, 2019
Assignees:
INSTITUT PASTEUR, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS
Inventors:
Michaela Müller-Trutwin, Mickaël J. Y. Ploquin, Matthew Albert, Yoann Madec, Cécile Goujard, Laurence Meyer
Abstract: The invention relates to a method for the treatment or prevention of an influenza virus infection in a subject, the method comprising administering to the subject a therapeutically effective amount of a gamma-irradiated influenza virus.
Abstract: This invention relates to adjuvant formulations comprising various combinations of triterpenoids, sterols, immunomodulators, polymers, and Th2 stimulators; methods for making the adjuvant compositions; and the use of the adjuvant formulations in immunogenic and vaccine compositions with different antigens. This invention further relates to the use of the formulations in the treatment of animals.
Type:
Grant
Filed:
April 26, 2017
Date of Patent:
March 26, 2019
Assignee:
Zoetis Services LLC
Inventors:
Paul Joseph Dominowski, Ramasamy Mannar Mannan, Richard Lee Krebs, James Richard Thompson, Tedd Alan Childers, Mary Kathryn Olsen, Robert John Yancey, Jr., Risini Dhammika Weeratna, Shucheng Zhang, Cedo Martin Bagi
Abstract: Methods and systems for purifying cells and/or viruses are provided. The sample is added to a well disposed in a medium. A potential is applied across the medium to cause the contaminants to enter one or more walls of the well, and retain the cells and/or viruses in the well. The cells and/or viruses can be removed from the well, and optionally adhered or fixed to a surface, or detected. In one embodiment, the cells and/or viruses may be retained in the well by embedding in the medium. The medium including the embedded cells and/or viruses may be excised or otherwise removed and transferred to a glass slide or other solid surface.
Type:
Grant
Filed:
August 12, 2016
Date of Patent:
February 12, 2019
Assignee:
Accelerate Diagnostics, Inc.
Inventors:
Steven W. Metzger, Kenneth Robert Hance
Abstract: The present invention relates to a hybrid vaccine for protecting a feline against diseases associated with respiratory diseases. The vaccine commonly includes a feline antigen. Methods for protecting felines against diseases associated with feline gastrointestinal and respiratory diseases, including but not limited to feline calicivirus, feline rhinotracheitis and feline panleukopenia, and methods of producing the feline vaccine are also provided.
Abstract: Disclosed herein are compositions comprising a Human Immunodeficiency Virus (HIV) trans-activator of transcription (Tat) derivative polypeptide with increased immunostimulatory properties relative to the native Tat polypeptide, pharmaceutical compositions comprising the Tat derivative polypeptide, and methods of treating cancer using the Tat derivative polypeptide.
Abstract: The invention refers to a method for producing an antigen comprising at least one hydrophobic or partially hydrophobic antigen molecule from a virus, a bacterium, fungus, protozoan, parasite, a human neoplastic cell or an animal neoplastic, tumor or 5 cancer cell, the method comprising the steps of providing a virus, or cell comprising an antigen molecule, purifying the cell comprising the antigen molecule, solubilizing the antigen molecule in a solubilizing agent that preserves an intact antigen molecule upon solubilization and reconstituting the antigen molecule in a lipid-binding polypeptide that provides a lipid membrane mimicking environment and a reconstituted antigen particle 10 obtained by this method.
Type:
Grant
Filed:
September 12, 2014
Date of Patent:
December 25, 2018
Assignee:
Sallpro Biotech AB
Inventors:
Robin Löving, Jens Frauenfeld, Gunilla Karlsson Hedestam, Henrik Garoff, Mathilda Sjöberg